A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...

Researchers say the reduction was influenced by the combined effects of changes in infection prevention and control, ...

Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...

By Dennis Thompson HealthDay ReporterTHURSDAY, April 9, 2026 (HealthDay News) — Prompt treatment with a fecal transplant can ...

A new study from the University of Minnesota Medical School has demonstrated that fecal microbiota transplantation (FMT) can ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Incidence rates of health care-associated Clostridioides difficile infection were 3 times higher in patients with COVID-19 than those without coronavirus infection in a Serbian hospital. CDI is a ...

A large team of microbiologists, pathologists and infectious diseases specialists affiliated with several institutions in the U.S. has developed an mRNA vaccine that has thus far been found able to ...

Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...

A new study from the University of Minnesota Medical School demonstrated that fecal microbiota transplantation (FMT) can rapidly reverse systemic inflammation and improve survival in patients with ...

Increased risks observed for analgesics and corticosteroids, among others, in Swedish stud ...

A total of 54% of adults in the United States were “not at all” familiar with clostridioides difficile (C. diff), a bacterial infection that causes nearly 30,000 deaths in the US each year, according ...